
補è¬äŒæ¥ç ç©¶ã補è¬ç ç©¶è·å°±æŽ»ããã€ãªãã³ãã£ãŒç ç©¶çã«ã€ããŠããã°æçš¿âïžïœ 倧æå è³è£œè¬ è¬çç ç©¶è·ð§«ïœãã€ãªã€ã³ãã©å匷äžð»ïœ ã³ã³ãã©ã§å°±æŽ»çžè«ãåããŠãŸãïŒïœ #補è¬/#ç ç©¶è·/#å°±æŽ»ïœ â»çºèšã¯æå±ã代衚ããŸããïœâ»è£œè¬ã«é¢ä¿ãªãããšã¯ãã€ãŒãããŸãã
æ±äº¬
Joined January 2020
- Tweets815
- Following440
- Followers4.9K
- Likes9.2K
ã賌å
¥é ããŸããïŒ
æ¥æããå°±æŽ»ãæ¬æ ŒåããŸããã補è¬ãå¿æããæ¹ã¯ä»¥äžã®çåããæã¡ã§ã¯ïŒ
ã»åäŒç€Ÿã®å°æ¥ã¯å€§äžå€«ãªã®ïŒ
ã»ã©ããªç ç©¶ç°å¢ïŒ
ã»ç ç©¶è·ã¯äžçå®éšããïŒ
å
šãŠã®çåã«å
šåã§çããŸã
補è¬äŒæ¥ãžã®å°±è·ã«é¢ããçåã«ç¡å¶éã§çããŸã | ã³ã³ãã© coconala.com/services/156391âŠ
ååããªã³ããã§ãšããïž
rocatinlimab(OX40æäœ)ã®Ph3詊éšã§PoCç²åŸïŒïŒ
ããã¯ãŸããããã¯ãã¹ã¿ãŒãïŒïŒ
ããªã³ã¯è³ãã«åã£ãïŒïŒð
OSãäžã«åŒµãä»ããŠãã ãããç¬
ãã£ã±ãLAG3ã£ãŠæå³ããããããð€
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
By @MyriamChalabi & colleagues in @NatureMedicine
nature.com/articles/s41591-0âŠ
Not sure much more mind blowing the pathologic response or OS in this setting can be! #ESMO24
3
6,492
ãšãŒã¶ã€ã®ã¬ã±ã³ããEU(EMA)ããæ¿èªã«ã€ããŠãã¬ãã£ããªã³ã¡ã³ããåããŠãŸããã
ãªã¹ã¯ã«å¯ŸããŠããããã£ãã(è¬å¹)ãå°ãããšã®ã³ã¡ã³ãã®ããð§
ãªã¢ã«ã¯ãŒã«ãã§ã®çµæã§ã³ã¡ã³ããèŠããããªãããã£ããã瀺ããããããããð€
BREAKING NEWS: EU regulatory panel says Leqembi should not be approved $BIIB firstwordpharma.com/story/58âŠ
ðãã£ãŒã@補è¬ã®å
šãŠãç¥ãããç ç©¶è
retweeted
æäœç ç©¶è
ãå¿
èŠð
æäœå»è¬åã®ãããã©ã³ããŒã»äžå€è£œè¬ã®ä¿æãã14åãã¹ãŠã®ç¬èªæäœæè¡ãåããããã解説ãããµã€ãã§ãðââïž
ãããçºããŠãããšäžå€ããã®ããããåãããããããããã«çºå±ãããã¢ã€ãã¢ãæãä»ãããã§ãïŒ
chugai-pharm.co.jp/profile/pâŠ
ASCO2024泚ç®ãããã¯ð¥
DESTINY-BREAST06詊éš
ãšã³ããŒãã®HER2-ultralowã§HER2-lowãšã»ãŒåãå¥å¹ð
ORR:lowâ56.5 ultraâ61.8
PFS:lowâ13.2 ultraâ13.2
é質æ§èºçŸæ£ã¯å°ãå€ãã®ã§ã泚æãå¿
èŠã ããããã¯ãã©ãã€ã ã·ããð§
Dato-Dxdã¯å°ãæ®å¿µã ã£ããããšã³ããŒãã¯å¥œèª¿
#ASCO24
#ASCO24
DESTINY-Breast06: T-DXd vs TPC in pts with HR+/ HER2-low or HER2-ultralow
PFS
Lowâ¡ïž13.2 vs 8.1 mo
Ultralowâ¡ïž13.2 vs 8.3 mo
ORR
Lowâ¡ïž56.5 vs 32.2%
Ultralowâ¡ïž61.8 vs 26.3%
ILDâ¡ïž11.3% (0.7% Gr3/4, 0.7% Gr5) vs 0.2% (Gr2)
âïžAttention should be paid to ILD
ð¥Even if HER2 is very very low (shy), T-DXd is effective
@curijoey @OncoAlert
ãšãŒã¶ã€ã®æ±ºç®ð
â
ã¬ã±ã³ããå幎床43ååïŒæ¥å¹Žã¯565ååãèŠèŸŒãð¥
â
3000åå売ãäžããŠããã¬ã³ããã¯2026幎é ã«ç¹èš±åã
ã¬ã³ããã®ã¯ãªãã«å¯ŸããŠã¬ã±ã³ããé 調ã«äŒžã³ãã°ã¯ãªãã¯åé¿ãïŒð§
ããšã¯çé åã®ããã«ADCã®æåãæ¬²ããã§ããð€š
3Lç¬
1
15
9,328
äœåãã¡ãŒãã®æ±ºç®ð
â
åžå°ãããšiPSãä»åŸã®ã¡ã€ã³
â
ããŒãã³ãœã³iPSã¯ä»å¹ŽåºŠã«æ¿èªååŸäºå®
â
ç¡é
åœäºå®ð«
èµ€åã瀟é·äº€ä»£ã¯çãããåç¥ãªã®ã§å²æ
倧éã®éçºåãäžæ¢ð§ããã¢ãããšã«ããçž®å°ã
åœåã¯ç®ç«ã£ãäžåžäºå®åããªãã®ã§ãã©ãæã¡çŽããð§iPSäžç¹è³ãïŒ
1
43
13,342
å¡©é矩補è¬ã®ç·æ±ºç®ð
â
HIVãšææçè¬ã§å¢åå¢çð¥
â
ãŸã³ãŒãUS Ph3ã¯äž»èŠé
ç®æªéð«
â
5/24ã®ã¯ã¯ãã³å¯©æ»ã泚ç®
â
æè¥æºè¬ã®ããŒã¿ã6/7å
¬éïŒ
ãŸã³ãŒãã¯ãã®ãŸãŸæ£ã£ãŠããŸãã®ãïŒä»è©Šéšã§ç²ããïŒ
æè¥æºè¬ãã¯ã¯ãã³ãªã©ç€Ÿéããããçµæãç®çœæŒã
HIVããããã¡ã«æ¬¡ã®æ±ãäœãããïŒ
äœåãã¡ãŒãã®ããã³ãã£ã¢äºæ¥ã¯åäŒç€Ÿã«åãé¢ãð
å»è¬åããããã£ãã®ã«ããã³ãã£ã¢ã«ç§»åãããããŠãåäŒç€Ÿã«ç°åã«ãªã人ãããã®ããªããããããð
å°éè¬åã®ç·æ±ºç®ð
â
売äžã¯9æé£ç¶å¢ã6æé£ç¶å©çå¢ð
â
ããããæ¥å¹Žã¯è¬äŸ¡æ¹å®ãã¡ã«ã¯ã®ãã€ã€ã«ãã£æžå°ãªã©ã§500åæžã®äºæ³
è³æãããªãèŠããããªã£ãïŒåãæé·ð
2024-25æ¿èªäºå®ã®éçºåãå
šç¶ãªãð€
2026幎以éã«åºãããªåãèŠåœãããªã
è²·åããDeciphera瀟ãäžæãæŽ»çšããã
ããããããð
ããžãç¬
å±±äžå
çãšãå察ããªãã®ããç¬
>顧客æ¬äººã®çްèã§ã€ãã£ãiPS现èã䜿ãçŸå®¹ååäºæ¥ãå§ãããšçºè¡šãããè¡æ¶²ãªã©ããiPS现èãã€ãããæœåºããæå¹ãªæåãæ··ããçŸå®¹æ¶²ãåç²§æ°Žãã€ããã
ã³ãŒã»ãŒãiPS现èããçŸå®¹æ¶²ã蚺æä»ãã§å¹Ž100äžå
nikkei.com/article/DGXZQOUC0âŠ
1æ¬12äžå以äžã®çŸå®¹æ¶²6æ¬ãå»çæ©é¢ã§ã®è蚺æãããã±ãŒãžåãå®èšŒå®éšãå§ãã2026幎床ãŸã§ã«ãµãŒãã¹ãæäŸããŸããäžåœãåç±³ã§ãäºæ¥ãå±éããŸãã
15
7,396
ååããªã³ã®1Q決ç®ð
â
ã¯ãªãŒã¹ããŒã¿ããã€ã€ã«ãã£ã§åŸ®å¢åå¢ç
â
è²·åããOrchard瀟ã®Libmeldyãåé11ååð§å幎床ã§45ååæ³å®
å
šäœçã«ãããŸã§æ³šç®ãã¹ãçºè¡šã¯ãªãã§ããã
FDAæ¿èªãã¡ãããšåããã®ã§ãOrchard瀟ã®HSC-GTæè¡ããã¯æ¬¡ã
ãšè£œåãåºããããïŒ
倧å¡HDã®1Q決ç®ð
â
ã°ããŒãã«4補åãé 調ðãã³ãµãŒãã¯50%å¢ïŒä»ã20%å¢
â
ãµããªãšããæå€ãšãã£ã¡ãå¢ããŠãð21ïŒ
å¢
â
ã®ãªã¢ãäž»äœã®PD-1+TIGITã®Ph3詊éšãšã楜ãã¿ã§ãããªããªð§
â
Visterra瀟æè¡ã§äœã£ãVIS649ãæåãããFocus areaãšããŠPoCç²åŸãããªãïŒðç¬
䌞ã³ä»£ãããªããªã
æžææå€±ãšã¯ãæè³ãååã§ããªãèŠèŸŒã¿ãåºãå Žåã«ããã®èŠèŸŒã¿ã財å諞衚ã«åæ ãããåŠçã§ã
ã€ãŸããããã€ãã§ã³ããªãŒã¯æåæ³å®ãããã売ããŠãªããðèŠèŸŒãã§ãè³ç£ãæžãããã£ãŠããš
ããããã¿ããªæãåºããŠæ¬²ããããžã§ã ããµããªã«ãŽãã¯ã¹ãæ®ã£ãŠããããšãðãŸã æžæããããïŒ
äœåãã¡ãŒãã24幎3æææ¥çžŸã¯3150ååã®æçµèµ€åã«
åå®®çè
«ã»åå®®å
èçæ²»çè¬ããã€ãã§ã³ããªãŒãã®ç¹èš±æš©ã®æžææå€±ïŒ1335ååïŒãªã©ãèšäžããåŸæ¥äºæ³ïŒ1410ååã®èµ€åïŒããæå€±ãæ¡å€§
sumitomo-pharma.co.jp/news/aâŠâŠ



































